Perinatal Biologics Supplier for Honolulu Orthopedic Centers

Documentation Orthopedic Groups Ask For First

Before an orthopedic practice or surgery center adds a new biologics vendor, the usual first step is a documentation request rather than a sales conversation: a certificate of analysis for the lot in question, a donor eligibility summary covering medical and social history review and serology testing, and confirmation that the lot passed third-party sterility testing after a quarantine hold.

Precision Biologics makes all of this available to verified accounts, since donors are mothers who consent to donate at the time of a scheduled, full-term C-section and whose option to separately bank cord blood is unaffected by that donation.

NPI Verification and Account Access

Opening an account starts with an NPI number, which we use to confirm the practice or surgery center is an active, licensed entity before any order is processed. From there, verified accounts can request a peer-to-peer documentation call covering processing, testing, and specifications; these calls stop short of clinical or dosing advice, which stays with the practice and its own physicians.

Cold-Chain Shipping to Honolulu Accounts

Cryopreserved Wharton's jelly products are slow-rate frozen, held at -80 degrees C, and shipped overnight on dry ice in validated containers using the same nationwide logistics process used for every account, including those in Honolulu. Lyophilized formats ship and store at room temperature per the insert included with the lot. Clinics are expected to record lot numbers at the patient record level once a shipment arrives, which keeps the chain traceable from donation lot to use.

Confirming Regulatory Standing Locally

Determining whether a particular use of a Wharton's jelly product is minimally manipulated, homologous, and non-systemic under 21 CFR 1271.10 is up to the practice and its counsel, not something Precision Biologics opines on. Exosome products are generally treated as biologic drugs rather than section 361 tissue products, and FDA has stated plainly that no exosome product holds current approval.

Before adding either product line, we recommend an orthopedic group confirm its own standing with the Hawaii Medical Board and separately with its legal counsel. These products are not FDA approved or licensed for any disease or condition; this page is intended for licensed healthcare professionals and is not medical or legal advice.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.